Imidapril - Antihypertensives-(Feb 2004)
Drug Name:
Imidapril - Antihypertensives-(Feb 2004)
List Of Brands:
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Additive hyperkalemic effects with potassium sparing diuretics, K supplements and other hyperkalemic drugs. Reduced antihypertensive effects or additive renal effects with NSAIDs Marked hypotension with diuretics, other antihypertensives, alcohol other agents that lower BP
Indication:
LIST OF DRUGS DURING 2004
Sr.No- 190
Name of the Drug- Imidapril
Pharmacological Classification- Anti-hypertensive
Date of Approval- 23-02-2004
Approved by U.S.FDA on 30-12-2004 (Ref- FDA approved List- 2004)
New drugs approved For Marketing by Drug Controller General of India(DCGI )
during the period January 1988 to November 2014
(Ref- IDMA Annual Publication 2015)
Name of Drug Indication Date of Approval
Imidapril Anti-hypertensive 23-02-2004
Mild to moderate hypertension
Adverse Reaction:
Adverse drug reactions like cough ,headache, fatigue, GI and taste disturbances, persistent dry cough, other resoiratory tract symptoms, skin rash, angioedema, Photosensitivity, renal impairment, hyperkalemia, hyponutremia, blood disorders, proteinuria, tachycardia, stomatitis, pancreatitis, Cholestatic jsaundice, alopecia, muscle cramps, paraesthesias, mood and sleep disturbances, impotence. Excessive hypotension which result in MI or stroke in patients with ischemic heart disease or cerbrovasscular disease .
Contra-Indications:
Aortic stenosis or outflow tract obstruction Renovascular diseases. Ascites Pregnancy and lactation
Special Precaution
Peripheral vascular diseases, generalised artherosclerosis, idiopathic heridatory angioedema, heart failure , patients likely to be salt or water depleted. Assess renal function before and during therapy. Monitor for proteinuria. Conduct regular WBC counts in SLE and scleroderma patients Discontinue diuretics 2-3 days before starting therapy and resume later if required Elderly.
Dosages/ Overdosage Etc:
Indication-
Mild to moderate hypertension
Dosage-
Treatment initiated with 5mg once daily . The dose should be titrated to give optimum control of blood pressure
Pharmacology/ Pharmacokinetics:
Pharmacology
The hypotensive effect of imidapril in hypertension appears to result primarily from the suppression of plasma rennin-angiotensin-aldosterone system. Inhibition of ACE results from decreased plasma angiotensin II which leads to decreased vasopresser activity and to reduced aldosterone secretion.
Pharmacokinetics
Following oral administration Imidapril is rapidly absorbed from from the gastrointestinal tract and reaches its maximum plasma concentration within 2 hours. Half life is about 2 hours. Absorption is about 70% and the absolute bioavailability of imidapril is about 70% and the absolute bioavailability of imidapril is about 20% Plasa concentration of Imidapril has an initial half-life of about 7-9 hours and a terminal half life of more than 24 hours.
Pregnancy and lactation:
Contrindicated for use during pregnancy and lactation. Use with extreme caution if needed